(Q35842525)

10 August 2017

1 reference

title

Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy (English)

1 reference

10 August 2017

1

Robert W Buckheit

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

933-958

1 reference

Comparative pharmacokinetics of antiviral nucleoside analogues

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Synthesis and biological properties of novel pyridinioalkanoyl thiolesters (PATE) as anti-HIV-1 agents that target the viral nucleocapsid protein zinc fingers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Recombinant retroviral systems for the analysis of drug resistant HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Fitness of drug resistant HIV-1: methodology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

The role of genotypic heterogeneity in wild type virus populations on the selection of nonnucleoside reverse transcriptase inhibitor-resistant viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Predicting the unpredictable: transmission of drug-resistant HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

The frequency of resistant mutant virus before antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain: effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DN

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Use of chimeric human immunodeficiency virus types 1 and 2 reverse transcriptases for structure-function analysis and for mapping susceptibility to nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Human immunodeficiency virus type 1 replication in the absence of integrase-mediated dna recombination: definition of permissive and nonpermissive T-cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Identification of a new human immunodeficiency virus type 1 distinct from group M and group O.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Near-full-length genome sequencing of divergent African HIV type 1 subtype F viruses leads to the identification of a new HIV type 1 subtype designated K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

HIV drug resistance and viral fitness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Implications of antiretroviral resistance on viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Practical applications of viral fitness in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Fitness variations and their impact on the evolution of antiretroviral drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Virological and immunological characteristics of HIV treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

The kinetics of human immunodeficiency virus reverse transcription are slower in primary human macrophages than in a lymphoid cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Processivity and drug-dependence of HIV-1 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.933

10.1517/13543784.13.8.933

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference